Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | UBE2N | P61088 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4616558 | 0.88 | LMNA (0.43) | KMT2AMEN1UBE2NMAPTALDH3A1 | |
| SCHEMBL4615816 | 0.86 | ELANE (0.45) | KMT2AMEN1MAPTALDH1A1ALDH3A1 | |
| SCHEMBL4613938 | 0.82 | MAPT (0.47) | KMT2AMAPT | |
| SCHEMBL4613618 | 0.82 | HTR6 (0.48) | KMT2AMEN1UBE2NTDP1MAPT | |
| Hydrochloric Acid SCHEMBL4614741 | 0.81 | HTR6 (0.47) | KMT2AMEN1UBE2NTDP1MAPT | |
| SCHEMBL4615639 | 0.79 | ALDH1A1 (0.44) | KMT2ACA1CA2CA9ALDH1A1 | |
| SCHEMBL4614431 | 0.76 | GPR119 (0.48) | KMT2AMEN1MAPTGAATP53 | |
| SCHEMBL27798166 | 0.74 | GRM2 (0.39) | KMT2AMEN1UBE2NTDP1ALDH1A1 | |
| SCHEMBL3860379 | 0.72 | CA2 (0.56) | KMT2AMEN1UBE2NTDP1MAPT | |
| SCHEMBL4615355 | 0.70 | HTR6 (0.43) | UBE2NALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365063-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365063-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365063-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1708713-B1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D)(1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | HOFFMANN LA ROCHE (CH) | 2008-03-12 | — | — | EP | disclosed |
| US-20070149510-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-06-28 | — | — | US | disclosed |
| US-20070149510-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-06-28 | — | — | US | disclosed |
| US-20070149510-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2007-06-28 | — | — | US | disclosed |
| US-7196087-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196087-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196087-B2 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-03-27 | — | — | US | disclosed |
| EP-1708713-A1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D)(1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | F. Hoffman-la Roche AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| WO-2005067933-A1 | 1-BENZYL-5-PIPERAZIN-1-YL-3,4 DIHYDRO-1H-QUINAZOLIN-2-ONE DERIVATIVES AND THE RESPECTIVE 1H-BENZO(1,2,6)THIADIAZINE-2,2-DIOXIDE AND 1,4-DIHYDRO-BENZO(D) (1,3)OXAZIN-2-ONE DERIVATIVES AS MODULATORS OF THE 5-HYDROXYTRYPTAMINE RECEPTOR (5-HT) FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM | F. HOFFMANN-LA ROCHE AG (CH) | 2005-07-28 | — | — | WO | disclosed |
| US-20050165001-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2005-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149510-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | NQO2, MLX, CYP4X1 | KMT2A 2123/4885MEN1 1069/4885UBE2N 872/4885 |
| US-20050165001-A1 | Quinazolinone and benzoxazinone derivatives and uses thereof | NQO2, MLX, CYP4X1 | KMT2A 2123/4885MEN1 1069/4885UBE2N 872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.